Opus Genetics Aligns With FDA In A Type B Rare Disease Meeting On Design Of Its Registrational Phase 3 Clinical Trial Evaluating OPGX-lCA5 For Early-Onset Severe Inherited Retinal Dystrophy

Loading news article.

Opus Genetics Aligns With FDA In A Type B Rare Disease Meeting On Design Of Its Registrational Phase 3 Clinical Trial Evaluating OPGX-lCA5 For Early-Onset Severe Inherited Retinal Dystrophy | WAPE

Opus Genetics Aligns With FDA In A Type B Rare Disease Meeting On Design Of Its Registrational Phase 3 Clinical Trial Evaluating OPGX-lCA5 For Early-Onset Severe Inherited Retinal Dystrophy

Article summary

Related companies

Comments —